Latest Insider Transactions at Kymera Therapeutics, Inc. (KYMR)
This section provides a real-time view of insider transactions for Kymera Therapeutics, Inc. (KYMR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kymera Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kymera Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2025
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
27,563
-73.49%
|
$2,260,166
$82.85 P/Share
|
|
Dec 17
2025
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
27,563
+30.88%
|
$964,705
$35.99 P/Share
|
|
Dec 17
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,595
+0.39%
|
$98,610
$38.53 P/Share
|
|
Dec 12
2025
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
678
-0.02%
|
$61,698
$91.04 P/Share
|
|
Dec 11
2025
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
6,101
-0.14%
|
$555,191
$91.23 P/Share
|
|
Dec 11
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
2,005,813
+19.01%
|
$172,499,918
$86.0 P/Share
|
|
Dec 10
2025
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
229,809
-0.99%
|
$20,682,810
$90.73 P/Share
|
|
Dec 08
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,307
-5.9%
|
$4,388,323
$89.77 P/Share
|
|
Dec 08
2025
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,307
+23.64%
|
$246,535
$5.33 P/Share
|
|
Dec 08
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-13.15%
|
$8,900,000
$89.17 P/Share
|
|
Dec 08
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+11.62%
|
$200,000
$2.08 P/Share
|
|
Dec 08
2025
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-77.48%
|
$445,000
$89.81 P/Share
|
|
Dec 08
2025
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$70,000
$14.18 P/Share
|
|
Oct 29
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-1.46%
|
$1,800,000
$60.73 P/Share
|
|
Oct 29
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.16%
|
$60,000
$2.08 P/Share
|
|
Oct 15
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
59,576
-10.13%
|
$3,634,136
$61.92 P/Share
|
|
Oct 15
2025
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,209
+14.01%
|
$51,209
$1.7 P/Share
|
|
Oct 13
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,114
-2.56%
|
$186,840
$60.0 P/Share
|
|
Oct 13
2025
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,473
+0.6%
|
$1,473
$1.7 P/Share
|
|
Oct 13
2025
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$295,000
$59.19 P/Share
|
|
Oct 13
2025
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$50,000
$10.34 P/Share
|
|
Sep 17
2025
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
79,220
-25.84%
|
$3,961,000
$50.0 P/Share
|
|
Sep 17
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
79,220
+20.53%
|
$158,440
$2.08 P/Share
|
|
Sep 16
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-4.34%
|
$1,470,000
$49.0 P/Share
|
|
Sep 16
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.16%
|
$60,000
$2.08 P/Share
|
|
Sep 03
2025
|
Brian Adams Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+50.0%
|
-
|
|
Jun 30
2025
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
317,167
+8.02%
|
$13,955,348
$44.0 P/Share
|
|
Jun 30
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
655,500
+9.15%
|
$28,842,000
$44.0 P/Share
|
|
Jun 11
2025
|
Elena Ridloff |
SELL
Open market or private sale
|
Direct |
4,500
-100.0%
|
$225,000
$50.0 P/Share
|
|
Jun 11
2025
|
Elena Ridloff |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+50.0%
|
$90,000
$20.29 P/Share
|
|
Jun 03
2025
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
6,349
-100.0%
|
$311,101
$49.0 P/Share
|
|
Jun 03
2025
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+50.0%
|
$63,490
$10.34 P/Share
|
|
Jun 03
2025
|
Nello Mainolfi Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-4.34%
|
$1,470,000
$49.0 P/Share
|
|
Jun 03
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.16%
|
$60,000
$2.08 P/Share
|
|
Jun 03
2025
|
Elena Ridloff |
SELL
Open market or private sale
|
Direct |
12,000
-80.0%
|
$552,000
$46.25 P/Share
|
|
Jun 03
2025
|
Elena Ridloff |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+50.0%
|
$324,000
$27.67 P/Share
|
|
Jun 03
2025
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$245,000
$49.04 P/Share
|
|
Jun 03
2025
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$145,000
$29.55 P/Share
|
|
May 23
2025
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,575
-3.73%
|
$74,675
$29.3 P/Share
|
|
Apr 08
2025
|
Noah Goodman Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.96%
|
-
|
|
Mar 31
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+9.93%
|
$50,000
$2.08 P/Share
|
|
Mar 03
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,740
-2.3%
|
$172,200
$30.67 P/Share
|
|
Mar 03
2025
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.26%
|
-
|
|
Mar 03
2025
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,035
-1.69%
|
$211,050
$30.67 P/Share
|
|
Mar 03
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+12.56%
|
-
|
|
Mar 03
2025
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,383
-1.0%
|
$41,490
$30.67 P/Share
|
|
Mar 03
2025
|
Jeremy G Chadwick Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+26.54%
|
-
|
|
Mar 03
2025
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,241
-1.37%
|
$67,230
$30.67 P/Share
|
|
Mar 03
2025
|
Ellen Chiniara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+25.04%
|
-
|
|
Jan 10
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.29%
|
$20,000
$2.08 P/Share
|